South Africa Diabetes Care Drugs And Devices Market: Market Size & Forecast 2026

The South Africa diabetes care drugs and devices market represents a significant healthcare sector within the Middle East and Africa region, valued at approximately $1.02 billion in 2025. The market is broadly divided into therapeutics, including insulin, GLP-1 receptor agonists, and oral antidiabetic drugs, and devices such as blood glucose meters, continuous glucose monitoring systems, and insulin pumps. South Africa's relatively well-developed healthcare infrastructure compared to other Sub-Saharan African nations positions it as a key market for both local and international diabetes care providers.

• •The overall market is projected to expand at a 5.7% CAGR through 2029
• •Drugs account for roughly two-thirds of total market value, devices for the remainder
• •The insulin sub-market alone is forecast to reach $198.3 million by 2030 at a 5.4% CAGR

The rising prevalence of type 2 diabetes in South Africa, driven by urbanization, sedentary lifestyles, and dietary shifts, remains the core demand catalyst. Government and private sector efforts to expand healthcare coverage, particularly through the National Health Insurance framework, are improving patient access to diabetes treatments and monitoring devices. Additionally, growing public awareness of diabetes management and rising screening rates are bringing more patients into formal care pathways.

• •Urbanization and lifestyle-related risk factors are pushing diabetes prevalence upward across the population
• •Public health initiatives and expanding insurance coverage are broadening access to care
• •Earlier diagnosis and disease awareness campaigns are enlarging the addressable patient pool

Therapeutics dominate the South Africa diabetes market, with insulin and oral antidiabetic drugs forming the bulk of revenues. The devices segment, particularly continuous glucose monitoring systems and smart insulin pumps, is growing at a faster clip than the broader market, reflecting global technology trends. Within South Africa, the Western Cape and Gauteng provinces, which concentrate private healthcare facilities and higher-income populations, account for the largest share of market activity, while public-sector demand is rising steadily.

• •The insulin market is expected to reach $198.3 million by 2030, growing at a 5.4% CAGR
• •Smart medical devices, including therapeutic devices, are projected at a 10.7% CAGR through 2030, outpacing the overall market
• •Geographic demand is concentrated in urban provinces with well-established private healthcare infrastructure

What are the recent trends and outlook?

The market is moving toward integrated digital health solutions, with CGM devices and connected insulin pumps gaining adoption among patients and clinicians. The launch of biosimilar insulins and next-generation monitoring devices is expected to sustain competitive dynamics and expand access across income levels. Long-term forecasts suggest the market will maintain its 5-6% CAGR trajectory through the early 2030s, supported by continued disease burden growth, healthcare system investments, and ongoing product innovation from global and local players.

• •Digital integration between glucose monitoring devices and health platforms is accelerating adoption of advanced devices
• •Biosimilar insulin launches are improving affordability and expanding the patient base
• •The market is expected to sustain a 5-6% CAGR through the early 2030s, with devices outpacing drugs in growth rate